Seaport Therapeutics, Inc. (NASDAQ:SPTX) Stock Rated “Moderate Buy” by Wall Street Analysts

Shares of Seaport Therapeutics, Inc. (NASDAQ:SPTX) have received a consensus rating of “Moderate Buy” from the twelve research firms that are currently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, three have issued a hold recommendation, six have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $38.57.

SPTX has been the subject of several analyst reports. Seaport Research Partners set a $46.00 target price on shares of Seaport Therapeutics in a report on Friday, September 25th. Raymond James Financial started coverage on shares of Seaport Therapeutics in a report on Friday, September 25th. They set a “strong-buy” rating and a $46.00 price target on the stock. UBS Group lowered shares of Seaport Therapeutics to a “sell” rating in a research report on Tuesday, June 9th. JonesTrading started coverage on shares of Seaport Therapeutics in a research note on Wednesday, August 26th. They issued a “buy” rating and a $32.00 price objective for the company. Finally, HC Wainwright restated a “buy” rating and set a $50.00 price objective on shares of Seaport Therapeutics in a research report on Thursday, September 10th.

Institutional Investors Weigh In On Seaport Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of SPTX. TRV GP VI LLC bought a new position in shares of Seaport Therapeutics in the second quarter worth about $44,769,742. Citadel Advisors LLC bought a new stake in Seaport Therapeutics during the 2nd quarter valued at approximately $4,152,000. The Manufacturers Life Insurance Company bought a new stake in Seaport Therapeutics during the 2nd quarter valued at approximately $1,793,000. State Street Corp purchased a new position in Seaport Therapeutics in the 2nd quarter worth approximately $1,448,000. Finally, Alyeska Investment Group L.P. purchased a new position in Seaport Therapeutics in the 2nd quarter worth approximately $1,629,000.

Seaport Therapeutics Price Performance

NASDAQ SPTX opened at $18.42 on Monday. The firm’s fifty day moving average is $22.67. Seaport Therapeutics has a fifty-two week low of $14.85 and a fifty-two week high of $28.38. The stock has a market capitalization of $986.02 million and a P/E ratio of -1.52.

Seaport Therapeutics (NASDAQ:SPTX) last issued its quarterly earnings results on Monday, August 3rd. The company reported ($1.78) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($1.07). Sell-side analysts anticipate that Seaport Therapeutics will post -4.52 earnings per share for the current fiscal year.

Seaport Therapeutics Company Profile

Seaport Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for neuropsychiatric and neurological disorders. The company’s research emphasizes therapies that modulate the brain’s GABAergic system, which plays an important role in mood, anxiety, and other central nervous system functions.

Seaport’s drug-development programs are based on its Glyph platform, a technology designed to improve the delivery of small-molecule medicines to the brain and enable oral versions of therapies that may otherwise require intravenous or other forms of administration.